Base-editing technologies along with AAV engineering not only help reduce costs but can also accelerate preclinical therapeutic development.

SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular ...

Sponsored content brought to you by ATTCGA ➜ ATTCCA That’s gene editing. On paper, it is merely the rearrangement of letters.